These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 7714978

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. A preliminary report from a randomized multicenter study.
    Lundgren R, Sundin T, Colleen S, Lindstedt E, Wadström L, Carlsson S, Hellsten S, Pompeius R, Holmquist B, Nilsson T.
    Scand J Urol Nephrol; 1986; 20(2):101-5. PubMed ID: 3529368
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cisobitan in treatment of prostatic cancer. A prospective controlled multicentre study.
    Alfthan O, Andersson L, Esposti PL, Fosså SD, Gammelgaard PA, Gjöres JE, Isacson S, Rasmussen F, Ruutu M, von Schreeb T, Setterberg G, Strandell P, Strindberg B.
    Scand J Urol Nephrol; 1983; 17(1):37-43. PubMed ID: 6346476
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group.
    Iversen P, Rasmussen F, Asmussen C, Christensen IJ, Eickhoff J, Klarskov P, Larsen E, Mogensen P, Mommsen S, Rosenkilde P.
    J Urol; 1997 Mar; 157(3):929-34. PubMed ID: 9072602
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S.
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of prostatic cancer: effects on serum lipoproteins and the cardiovascular system.
    Rössner S, Hedlund PO, Jogestrand T, Säwe U.
    J Urol; 1985 Jan; 133(1):53-7. PubMed ID: 3964880
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate.
    Henriksson P, Eriksson A, Stege R, Collste L, Pousette A, von Schoultz B, Carlström K.
    Prostate; 1988 Jan; 13(3):257-61. PubMed ID: 3211807
    [Abstract] [Full Text] [Related]

  • 16. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
    Karr JP, Wajsman Z, Kirdani RY, Murphy GP, Sandberg AA.
    J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The oestrogenic effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate in patients with prostatic carcinoma. A comparative study of oestrogen sensitive liver proteins, gonadotrophins and prolactin.
    Daehlin L, Damber JE, von Schoultz B, Bergman B.
    Br J Urol; 1986 Aug; 58(4):412-6. PubMed ID: 3092893
    [Abstract] [Full Text] [Related]

  • 20. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
    Kelly WK, Halabi S, Elfiky A, Ou SS, Bogart J, Zelefsky M, Small E, Cancer Leukemia Group B.
    Cancer; 2008 Dec 01; 113(11):3137-45. PubMed ID: 18989865
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.